Related by context. All words. (Click for frequent words.) 79 label multicenter 75 label multicenter Phase 74 label multicenter randomized 72 dose escalation study 72 dose escalation trial 71 Phase III randomized 70 multicenter randomized 69 randomized multicenter 69 safety tolerability pharmacokinetics 68 dose escalation Phase 68 label dose titration 68 dose dose escalation 67 tolerability pharmacokinetics 67 controlled multicenter 67 placebo controlled clinical 67 placebo controlled 67 placebo controlled Phase 67 multicenter Phase II 67 blind randomized placebo 66 placebo controlled randomized 66 randomized placebo controlled 66 multicenter randomized double 66 Phase Ib 66 phase Ib 66 ascending dose 66 multicenter Phase 66 multicenter 66 Phase IIIb 65 randomized controlled Phase 65 randomized Phase III 65 Phase 1b 65 placebo controlled Phase III 65 Phase 2a clinical 65 randomized controlled 65 Phase #/#a 64 multicentre randomized double 64 blinded randomized placebo controlled 64 treatment naive genotype 64 masked placebo controlled 64 pivotal Phase 64 ongoing Phase 1b 64 prospective randomized 64 Phase 1b trial 64 dose escalation clinical 64 phase IIb clinical 64 Phase III multicenter 64 multicenter Phase III 64 multicenter randomized placebo controlled 64 prospective multicenter 63 blinded placebo controlled 63 multicentre 63 Phase Ib clinical 63 Phase Ib II 63 pharmacokinetics PK 63 double blinded placebo 63 tolerated dose MTD 63 blind randomized 63 double blinded randomized 63 phase IIb 63 dose escalation 63 safety tolerability 63 BRIM2 63 double blind placebo 63 blind placebo controlled 63 LUX Lung 63 TMC# C# 63 Phase 2a 63 placebo controlled dose escalation 63 prospective randomized controlled 63 multicenter prospective 62 prospective multicenter randomized 62 Phase 1b clinical 62 randomized double 62 Phase IIa trial 62 Phase 2b trial 62 Phase 2a trial 62 randomized #:# 62 randomized 62 Phase 2b study 62 Phase III placebo controlled 62 Sapacitabine 62 Phase Ib clinical trials 62 Phase 2b randomized 62 randomized Phase 62 blind multicenter 62 active comparator 62 oral deforolimus 62 Phase 2b clinical 61 multicentre randomized 61 ascending doses 61 ascending dose study 61 Phase IIa 61 Phase Ib study 61 Phase III Pivotal 61 randomized controlled multicenter 61 safety tolerability pharmacokinetic 61 Phase IIb trial 61 phase III ACCLAIM 61 HGS ETR1 61 Phase #b/#a 61 observer blinded randomized 60 multiple ascending dose 60 pharmacodynamics 60 IMC A# 60 phase IIa clinical 60 AIR2 Trial 60 controlled dose escalation 60 multicenter clinical 60 pharmacodynamic profile 60 HCV SPRINT 60 nonrandomized 60 randomized multicentre 60 Phase III pivotal 60 randomized Phase IIb 60 treatment naïve genotype 60 pivotal Phase III 60 randomized controlled clinical 60 Phase IIIb clinical 60 Phase IIa clinical 60 FOLOTYN ® 60 PRECiSE 60 dose cohorts 60 Initiated Phase 60 EOquin TM 60 registrational trial 60 alvespimycin 60 phase IIIb 60 rALLy clinical trial 60 prospective randomized multicenter 60 prospective observational 60 single ascending dose 60 Prospective Randomized 60 phase IIa 60 phase IIb study 60 phase Ib clinical 60 nab paclitaxel 60 registrational Phase 60 INCB# [001] 60 Phase III clinical 60 prospective randomized placebo 60 relapsed refractory multiple myeloma 60 dosing cohorts 59 dose cohort 59 randomized #:#:# 59 European Sepsis Trial 59 phase III SIMPADICO 59 Traficet EN 59 Initiate Phase 59 multicenter multinational 59 HGS ETR1 mapatumumab 59 Phase #b/#a clinical 59 COU AA 59 Phase Ib IIa 59 multicenter phase 59 forodesine 59 randomized clinical 59 EVEREST II 59 phase IIb trial 59 REVIVE Diabetes 59 INSPIRE Trial Phase III 59 intravitreal insert 59 Randomized Phase 59 CIMZIA TM certolizumab pegol 59 Multicenter 59 registrational 59 ZYBRESTAT fosbretabulin 59 confirmatory Phase III 59 Pivotal Trial 59 XL# XL# XL# 59 safety tolerability pharmacodynamics 59 Phase IIb clinical trials 59 investigational oral 59 de novo kidney transplant 59 symptomatic BPH 59 multicenter randomized controlled 59 ganetespib 59 multicenter placebo controlled 59 pharmacokinetic PK 58 dirucotide MBP# 58 Blinatumomab 58 II Clinical Trial 58 CEQ# 58 daily Infergen 58 tolerability 58 Zenvia Phase III 58 confirmatory Phase 3 58 Phase IIb clinical 58 DermaVir Patch 58 unique alkylating agent 58 IAP inhibitor 58 AIR CF1 58 pharmacokinetic PK study 58 recurrent malignant glioma 58 randomized blinded 58 randomized discontinuation trial 58 BRIM3 58 thorough QT 58 TAXUS V 58 PREZISTA r 58 oral prodrug 58 phase 2a 58 relapsing multiple sclerosis 58 velafermin 58 Phase 2b 58 relapsed multiple myeloma 58 sequential dose escalation 58 NP2 Enkephalin 58 NCCTG 58 VEGFR2 inhibitor 58 controlled multicenter Phase 58 mGluR5 negative 58 HCD# [002] 58 recurrent glioma 58 RG# [001] 58 sunitinib malate 58 plus Copegus R 58 sorafenib tablets 58 Phase III confirmatory 58 novel VDA molecule 57 viral kinetic 57 fosbretabulin 57 huN# DM1 57 Randomized Double blind 57 ROCKET AF 57 pertuzumab 57 blind placebo 57 HGS# 57 PSN# [002] 57 Phase III metastatic melanoma 57 Phase IIb 57 GEM OS1 57 placebo controlled multicenter 57 Phase IIIb study 57 refractory CLL 57 BR.# 57 prospectively randomized 57 randomized discontinuation 57 Sym# 57 pharmacokinetics 57 dose escalation phase 57 Phase 1b clinical trials 57 RE SURGE 57 Cutaneous T 57 RRMS patients 57 dose limiting toxicities 57 SUCCEED trial 57 unblinded 57 acute PAO 57 RG# ITMN 57 CR# vcMMAE 57 PRE SURGE 57 VICTOR E1 57 antibody MAb 57 fallopian tube cancers 57 BAY #-# 57 huC# DM4 57 PXD# 57 dose regimens 57 evaluating tivozanib 57 virus HCV protease inhibitor 57 Phase 1a 57 docetaxel Taxotere R 57 Aflibercept 57 PF # [001] 57 Allovectin 7 ® 57 GAMMAGARD 57 ENDEAVOR IV 57 crizotinib PF # 57 HuMax EGFr 57 ACTEMRA TM 57 Omacetaxine 57 PROPEL 57 analgesic efficacy 57 MGd 57 randomized crossover 57 relapsing remitting multiple sclerosis 57 Ophena TM 57 systemic RNAi therapeutic 57 Phase Ia 57 DAPT Study 57 Multicenter Randomized Double 57 #mg QD [002] 57 Hsp# Inhibitor 57 unresectable malignant mesothelioma UMM 57 HGS ETR2 57 Enzastaurin 56 neratinib 56 Perifosine 56 Deforolimus 56 blind randomized controlled 56 trial evaluating PRX# 56 TACI Ig 56 Pralatrexate 56 HCV NS5B polymerase 56 evaluating Xcytrin 56 ENESTnd 56 Phase III randomized controlled 56 Bayer HealthCare Onyx Pharmaceuticals 56 NO# [002] 56 docetaxel Taxotere ® 56 refractory cutaneous T 56 recurrent glioblastoma multiforme 56 AEG# 56 pharmacodynamic effects 56 CA4P 56 Phase 1a clinical 56 Imprime PGG 56 tanespimycin 56 MEK inhibitor RDEA# 56 ALN VSP Phase 56 dosing cohort 56 FAME Study 56 TAXUS VI 56 subcutaneous formulation 56 LibiGel Phase III 56 Alfimeprase 56 Kinesin Spindle Protein KSP 56 confirmatory clinical 56 axitinib 56 EchoCRT 56 Phase IIb III 56 Tanespimycin 56 dosage regimens 56 randomized Phase 2b 56 castrate resistant prostate cancer 56 non nucleoside inhibitor 56 ZYBRESTAT TM 56 investigational pan BCR 56 PDX pralatrexate 56 metastatic hormone refractory 56 riociguat 56 Pharmacokinetics PK 56 pharmacodynamic PD 56 stage IIIB 56 Phase 2b clinical trials 56 ExTRACT TIMI 56 nucleoside naive 56 lead Aganocide compound 56 EGFR HER2 56 APEX PD 56 Vascular Disrupting Agent 56 multinational multicenter randomized 56 metastatic HRPC 56 dosing regimens 56 Clinical Antipsychotic Trials 56 SCH # 56 PEG Interferon lambda 56 IMC #B 56 Phase III Clinical Trial 56 PREVAIL 56 Pivotal Phase 56 patients undergoing percutaneous 56 TAXUS ATLAS 56 Phase IIa trials 56 KRN# 56 blind multicentre 56 Annamycin 56 galiximab 56 MAGE A3 ASCI 56 GATTEX ® 56 Cannabinor 56 ADVANCE PD 56 refractory chronic lymphocytic 56 CTA# Injection 56 ThermoDox ® 56 either acutely decompensated 56 polycythemia vera essential thrombocythemia 56 IIa trial 56 dyskinesia PD LID 56 EURIDIS 56 pharmacokinetics pharmacodynamics 56 STEALTH C 56 APPRAISE 56 clinicaltrials 56 multicenter randomized clinical 56 Phase #b/#a trial 56 Phase 1b dose escalation 55 imetelstat GRN#L 55 PNP inhibitor 55 pharmacodynamics PD 55 Cell Lymphoma 55 clinical trial 55 Randomized Phase II 55 Denufosol 55 PRTX 55 ToGA 55 relapsing remitting MS RRMS 55 posaconazole 55 blinded randomized 55 blinatumomab 55 retinal vein occlusion induced 55 CLL8 55 LEVADEX 55 RADIANT 55 PRoFESS 55 GetGoal Phase III 55 histone deacetylase HDAC inhibitor 55 evaluating REVLIMID 55 low dose cytarabine 55 receptor tyrosine kinase inhibitor 55 CYT# 55 Phase III 55 sorafenib Nexavar ® 55 Fx #A 55 oral ridaforolimus 55 randomized multicenter trial 55 IL# PE#QQR 55 ARIKACE 55 AIR CF3 55 Diabetic Macular Edema 55 DU #b 55 Azedra 55 orally inhaled migraine 55 JAK inhibitor 55 Maximum Tolerated Dose MTD 55 RE LY ® 55 CCR5 mAb 55 docetaxel chemotherapy 55 MEND CABG 55 relapsed myeloma 55 EVIZON 55 landmark ATHENA 55 randomized blinded placebo 55 Panzem R NCD 55 toenail onychomycosis 55 MEND CABG II 55 oral sapacitabine 55 metastatic GIST 55 neovascular form 55 8mg/kg 55 dependent kinase inhibitor 55 RE LY 55 By JENNIFER LEARN 55 TELCYTA 55 mg/m2 cohort 55 Phase 2b Clinical Trial 55 PEGylated interferon beta 1a 55 mg administered orally 55 Phase 2b kidney transplant 55 vidofludimus 55 Phase IIb trials 55 Carfilzomib 55 severe oral mucositis 55 XIENCE V Stent System 55 CONQUER OB 55 erlotinib Tarceva ® 55 Augment Injectable 55 refractory multiple myeloma 55 CYT# potent vascular disrupting 55 designated HVTN 55 Zenvia ™ 55 LUMINATE 55 weekly subcutaneous injections 55 PI3K/Akt pathway inhibitor 55 Daclizumab 55 ELACYT 55 TG MV 55 bevacizumab Avastin ® 55 CML CP 55 mapatumumab 55 lymphoid malignancies 55 lintuzumab SGN 55 R#/MEM # 55 biliary tract cancer 55 Initiates Phase II 55 FOLFOX6 chemotherapy regimen 55 Microplasmin 55 ANCHOR trial 55 prospective multicenter study 55 dasatinib Sprycel ® 55 investigational humanized monoclonal antibody 55 advanced metastatic renal 55 generation purine nucleoside 55 Phase III psoriasis 55 Carotid Revascularization Endarterectomy vs. 55 Parkinson disease levodopa induced 55 Placebo Controlled 55 CIMZIA TM 55 liposomal formulation 55 Phase IIB 55 bevirimat Study 55 relapsed MM 55 oral rivaroxaban 55 sodium glucose cotransporter 55 GATTEX ™ 55 MSI #F 55 investigational drug 55 intravesical infusion therapy 55 orally bioavailable 55 Oral Fingolimod 55 Teriflunomide 55 desvenlafaxine succinate 55 prospectively defined 55 IIb clinical trial 54 atypical Hemolytic Uremic Syndrome 54 ABL inhibitor 54 lintuzumab 54 teriflunomide 54 9am 5pm Mon 54 pivotal bioequivalence 54 occlusion CRVO 54 SAR# [004] 54 Rindopepimut 54 AP# [003] 54 REALITY Trial 54 class mGluR5 inhibitor 54 Phase IIb randomized 54 PFO migraine 54 Phase III ALLEGRO 54 orally dosed 54 Elvitegravir 54 Randomized Double Blind Placebo 54 ONTARGET 54 recurrent malignant gliomas 54 chemotherapy FOLFOX 54 evaluating picoplatin 54 EINSTEIN DVT 54 CLORETAZINE TM VNP#M 54 velafermin belinostat 54 investigational protease inhibitor 54 compound INCB# 54 blind randomized multicenter 54 CBLC# 54 eculizumab 54 evaluating nimotuzumab 54 Hedgehog Pathway Inhibitor 54 Oral NKTR 54 Diabetic Macular Edema DME 54 Intervention Effectiveness 54 ABSORB clinical 54 EXPLORE Xa 54 KRAS mutations occur 54 allosteric modulator NAM 54 TPI ASM8 54 multicenter study 54 ACTEMRA 54 Tarvacin TM 54 papillary renal cell carcinoma 54 lorcaserin Phase 54 complement inhibitor eculizumab 54 PARTNER Trial 54 HER2 positive metastatic breast 54 comparing XIENCE V 54 JAK1 54 modified glutathione analog 54 pharmacokinetic 54 otelixizumab 54 Phase II 54 acute peripheral arterial 54 cilengitide 54 mGluR5 NAM 54 Azixa 54 Prostate Lung Colorectal 54 Pegasys ® 54 Tesetaxel 54 dacarbazine 54 PROTEGE 54 Entereg R 54 Placebo controlled 54 BCR ABL inhibitor 54 Dacogen injection 54 CURRENT OASIS 7 54 aflibercept VEGF Trap 54 REVLIMID lenalidomide 54 TG# [003] 54 sorafenib Nexavar 54 lorvotuzumab mertansine 54 RSD# oral 54 Multiple Ascending Dose 54 ATTRACT 54 initiate Phase 1b 54 Aplidin R 54 systemic Phase 1b 54 metastatic castration resistant 54 Phase IIb kidney transplant 54 refractory NSCLC 54 enzastaurin 54 CHAMPION PCI 54 Investigational Device Exemption IDE 54 TLK# 54 AIR CF2 54 nitazoxanide 54 inhibitor RG# 54 induced macular edema 54 CINQUIL 54 ARDIS 54 VNP#M 54 davunetide intranasal AL 54 CALGB # [002] 54 BrachySil TM 54 rapid virologic response 54 dacetuzumab 54 Anturol TM 54 virus HCV infection 54 recurrent metastatic ovarian cancer 54 Amrubicin 54 trastuzumab DM1 T DM1 54 Pivotal Phase III 54 evaluating satraplatin 54 Afatinib 54 evaluating Vectibix 54 PIX# [002] 54 rheumatoid arthritis psoriatic arthritis 54 COSIRA trial 54 factorial design 54 trastuzumab Herceptin R 54 Prostate AdenoCarcinoma Treatment 54 Seliciclib 54 TKB# 54 Tyrima 54 satraplatin Phase 54 Tarceva TM 54 ThermoDox R 54 Tolvaptan 54 elotuzumab 54 PEG PAL 54 mg BID 54 AEGR 54 CB2 selective receptor agonist 54 catheter occlusion CO 54 multicentric 54 Glufosfamide 54 Plicera 54 EDEMA3 54 intravesical instillation 54 AVADO 54 metastatic castrate resistant 54 adecatumumab MT# 54 hypoxia activated prodrug 54 dose titration 54 null responder HCV 54 OncoVEX GM CSF 54 denufosol 54 ABSORB trial 54 anticancer compound 54 Board DSMB 54 MEK inhibitor 54 noninferiority 54 Panzem R 54 Folfox 54 RGB # 54 OPT CHF 54 capecitabine Xeloda R 54 recurrent NSCLC 54 Cloretazine 54 PEG SN# 54 unresectable stage 54 sulodexide 54 prospective multicentre 54 IIa clinical 54 nucleoside analog 54 MIST II 54 retaspimycin 54 Aurexis 54 romidepsin 54 QD dosing 54 Early Relapsing Multiple 54 Sorafenib HCC Assessment 54 telaprevir dosing 54 Fovea Pharmaceuticals subsidiary 54 GEM OS2 54 pegylated interferon alfa 2a 54 VITAL Trial 54 DIRECT Trial 54 Phase III HEAT 54 farletuzumab 53 refractory metastatic colorectal cancer 53 Initiates Phase 53 refractory AML 53 OMP #M# 53 multicenter randomized Phase 53 Neovascular AMD 53 AAG geldanamycin analog 53 dirucotide 53 NGX# 53 evaluating MGCD# [002] 53 orally administered inhibitor 53 BENLYSTA ™ 53 PD LID 53 Akt inhibitor 53 Bezielle 53 SPIRIT FIRST 53 perifosine KRX 53 Triapine 53 TRO# 53 CATIE AD 53 ZYBRESTAT 53 Cloretazine ® 53 XL# SAR# 53 adult chronic ITP 53 primary hypercholesterolemia 53 ENVISION 53 Phase III clinical trials 53 multicenter dose escalation 53 HCV RESPOND 2 53 humanized anti 53 exemption IDE 53 estramustine 53 EMPHASIS HF trial 53 immunomodulatory therapy 53 CAMMS# 53 subanalysis 53 RANK Ligand inhibitor 53 cisplatin vinorelbine 53 REG2 53 Pivotal Study 53 ara C 53 2 methoxyestradiol 53 JAK2 inhibitor 53 non splenectomized 53 clinical trials Archexin ® 53 EOquin TM phase 53 opioid induced bowel dysfunction 53 Personalized Immunotherapy 53 Phenoptin 53 cariprazine 53 XL# anticancer compounds 53 TRAIL R1 53 randomized placebo 53 painful diabetic neuropathy 53 Atiprimod 53 lymphoma CTCL 53 novel histone deacetylase 53 PRIMO CABG2 53 PSMA ADC 53 NOX E# 53 APEX AMI trial 53 plus dexamethasone 53 mGluR2 positive 53 Genasense ® 53 evaluating pirfenidone 53 hyperphenylalaninemia HPA due 53 Phase IIb Trial 53 urate lowering 53 PRIMO CABG 53 Adalimumab 53 investigational monoclonal antibody 53 Albuferon TM 53 aflibercept 53 cell lymphoma CTCL 53 Dose escalation 53 PrevOnco ™ 53 dose pharmacokinetic 53 Combination REOLYSIN R 53 CTAP# Capsules 53 ILUVIEN ® 53 HuMax CD4 53 diabetic neuropathic pain 53 Quinamed 53 SYMMETRY trial 53 NATRECOR ® 53 metastatic pancreatic 53 LITHE 53 COMFORT II 53 Ofatumumab 53 monoclonal antibody IgG1 Mab 53 ancrod 53 Phase #/#a clinical 53 APTIVUS r 53 Elotuzumab 53 cannabinor 53 familial amyloidotic polyneuropathy FAP 53 Clinical Trial Evaluating 53 assessing T DM1 53 acute coronary syndromes ACS 53 VELCADE melphalan 53 Telik logo TELINTRA 53 chemotherapeutic regimen 53 Celacade TM technology 53 ORACLE MS 53 BENLYSTA ® 53 QLT# 53 neoadjuvant 53 teplizumab 53 systemic juvenile idiopathic 53 telaprevir dosed 53 gemcitabine carboplatin 53 RELOVAIR ™ 53 ADP receptor antagonist 53 cardio renal 53 INCB# [002] 53 icatibant 53 aplindore 53 PROSTVAC ® 53 relapsed refractory AML 53 ENGAGE AF TIMI 53 IMGN# 53 ADMIRE HF 53 Left Ventricular Dysfunction 53 intravitreal injection 53 NABTT 53 evaluating carfilzomib 53 Safinamide 53 hour bronchodilation 53 Hepatocellular Carcinoma HCC 53 vascular disrupting agent 53 Pivotal Clinical Trial 53 MIVI III 53 OLYMPIA registry 53 VEGF Trap 53 ID NCT# 53 interferon gamma 1b 53 mertansine 53 cutaneous T cell 53 APTIVUS 53 acyclovir Lauriad R 53 Study Evaluating 53 PRX # 53 maximally tolerated dose 53 EQUIP OB 53 selective phosphodiesterase 53 tgAAC# 53 peripherally acting 53 Archexin 53 placebo controlled clinical trials 53 PrevOnco 53 pomalidomide 53 recurrent glioblastoma 53 Vicinium TM 53 Allovectin 7 R 53 IMPACT DCM trial 53 Acute Ischemic Stroke 53 Blind Placebo Controlled Trial 53 systemic anaplastic large 53 myeloproliferative disorders 53 YONDELIS 53 Amigal 53 sapacitabine 53 JZP 53 Exherin TM 53 pan histone deacetylase 53 CALGB 53 Epothilone D 53 trastuzumab emtansine T DM1 53 budesonide foam 53 AA amyloidosis 53 ritonavir boosted 53 TAXUS IV 53 superficial bladder cancer 53 schizophrenia CIAS 53 refractory Hodgkin lymphoma 53 eniluracil 53 LymphoStat B TM 53 Naive Patients 53 ruxolitinib 53 MERLIN TIMI 53 CUSTOM III 53 visilizumab 53 investigational hepatitis C 53 efficacy tolerability 53 eosinophilic asthma 53 motesanib 53 Exelixis compounds 53 CEL SCI Phase III 53 omega interferon 53 TO AVOID PREGNANCY WHILE 53 Phase 2b Study 53 3 registrational trial 53 Ph + ALL 53 Val HeFT 53 ZACTIMA 53 metastatic neuroendocrine tumors 53 radiation sensitizer 53 unblinding 53 Radiation Therapy Oncology 53 histone deacetylase inhibitor 53 intradermal injections 52 CRMD# 52 AQ4N 52 Genasense ® oblimersen 52 AeroLEF TM 52 SIMPADICO 52 clevidipine 52 adecatumumab 52 AKT inhibitor 52 CK # administered 52 essential thrombocythemia ET 52 pharmacokinetic pharmacodynamic 52 depsipeptide 52 Genz # 52 Cloretazine R VNP#M 52 Phase IIb Clinical Trial 52 EXPAREL TM 52 dexpramipexole 52 chronic myeloid 52 topical formulation 52 ataluren 52 pharmacodynamic 52 Serdaxin ® 52 R roscovitine CDK cyclin 52 IMiDs ® compound 52 Golimumab 52 Randomized Double Blind 52 oral picoplatin 52 investigational compound 52 evaluable patients 52 PDE4 inhibitor 52 Pegasys R 52 delivers fluocinolone acetonide FA 52 PROPEL trial 52 Aryplase 52 generation PNP inhibitor 52 bendamustine 52 varespladib 52 CIMZIA R 52 placebo controlled studies 52 HDAC Inhibitor 52 Trial Evaluating 52 phase IIb III 52 ORENCIA ® 52 rNAPc2 52 ELND# 52 4mg/kg 52 Phase IIa Clinical Trial 52 lucinactant 52 venlafaxine XR 52 μg dose 52 leukemia AML 52 EmbraceAC 52 Inhalation Solution 52 Elagolix 52 Randomized 52 Chemophase 52 novel prodrug 52 forodesine HCl 52 Recurrent Glioblastoma 52 Phase III Clinical Trials 52 XmAb# 52 pheochromocytoma 52 pain palliation 52 ORMD 52 Voreloxin 52 AVONEX ® 52 specific CCR9 antagonist 52 SUTENT ® 52 DASISION 52 selective modulator 52 pharmacokinetic profile 52 heavily pretreated 52 multicentre randomized controlled 52 NOXAFIL Oral Suspension 52 plus methotrexate 52 TTF Therapy 52 number NCT# ClinicalTrials.gov 52 REOLYSIN ® 52 administered subcutaneously 52 talabostat 52 orally administered 52 Antiviral Activity 52 subcutaneous SC 52 RIBBON 52 EFAPROXYN 52 ILLUMINATE 52 CLARITY study 52 Novel Oral 52 systemically administered 52 kidney urologic 52 FOLFIRI chemotherapy 52 XL# XL# XL# XL# 52 catheter occlusion 52 nodular BCC 52 afatinib 52 IMPACT DCM 52 pralatrexate injection folate analogue 52 ocular hypertension 52 selective androgen receptor modulator 52 GALNS 52 KNS # 52 INCB# [003] 52 SPIRIT IV 52 CCX# 52 anti leukemic 52 Val MARC 52 fistulizing Crohn disease 52 injectable enzyme 52 stage IIIb IV 52 cetrorelix pamoate 52 relapsed CLL 52 TBC# 52 humanized therapeutic 52 Dose Ranging Study 52 paclitaxel poliglumex 52 Cloretazine R 52 LEP ETU 52 PMX # 52 #mg QD [001] 52 deforolimus 52 humanized monoclonal antibody 52 bile duct tumor 52 pralatrexate 52 mg/m2 dose 52 ferric citrate 52 MAP# 52 AVOREN 52 Endovascular Valve Edge 52 placebo controlled trials 52 oral antiviral 52 certolizumab pegol 52 headache nasopharyngitis